T-REGULATORY CELL KINETICS FOR PATIENTS RECEIVING ALEMTUZUMAB AND UNDERGOING STEM CELL TRANSPLANTATION FROM HLA MISMATCHED-RELATED OR ONE ANTIGEN MISMATCHED-UNRELATED DONORS.

Trial Profile

T-REGULATORY CELL KINETICS FOR PATIENTS RECEIVING ALEMTUZUMAB AND UNDERGOING STEM CELL TRANSPLANTATION FROM HLA MISMATCHED-RELATED OR ONE ANTIGEN MISMATCHED-UNRELATED DONORS.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2013

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Cytarabine; Mesna; Methotrexate; Tacrolimus
  • Indications Graft-versus-host disease; Hodgkin's disease; Leukaemia; Lymphoma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms REGALE
  • Most Recent Events

    • 01 May 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 30 Mar 2013 Planned End Date changed from 1 Dec 2015 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 30 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top